KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 151 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26 | -23.5% | 19,663 | +3.7% | 0.00% | – |
| Q2 2023 | $34 | -54.1% | 18,959 | -0.6% | 0.00% | – |
| Q1 2023 | $74 | -55.7% | 19,074 | -61.1% | 0.00% | – |
| Q4 2022 | $167 | -100.0% | 49,074 | -27.2% | 0.00% | -100.0% |
| Q3 2022 | $368,000 | +67.3% | 67,406 | +37.9% | 0.00% | – |
| Q2 2022 | $220,000 | -43.0% | 48,874 | -6.8% | 0.00% | – |
| Q1 2022 | $386,000 | +40.9% | 52,425 | +23.1% | 0.00% | – |
| Q4 2021 | $274,000 | +10.0% | 42,594 | -0.4% | 0.00% | – |
| Q3 2021 | $249,000 | -59.3% | 42,760 | -27.9% | 0.00% | -100.0% |
| Q2 2021 | $612,000 | -22.3% | 59,300 | -20.8% | 0.00% | 0.0% |
| Q1 2021 | $788,000 | -36.7% | 74,875 | -6.8% | 0.00% | 0.0% |
| Q4 2020 | $1,244,000 | +6.1% | 80,375 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,173,000 | -28.6% | 80,375 | -7.4% | 0.00% | -50.0% |
| Q2 2020 | $1,644,000 | +40.5% | 86,800 | +42.5% | 0.00% | 0.0% |
| Q1 2020 | $1,170,000 | +0.2% | 60,930 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $1,168,000 | +105.3% | 60,930 | +3.1% | 0.00% | 0.0% |
| Q3 2019 | $569,000 | +113.1% | 59,100 | +32.8% | 0.00% | – |
| Q2 2019 | $267,000 | +2.7% | 44,500 | 0.0% | 0.00% | – |
| Q1 2019 | $260,000 | -37.6% | 44,500 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $417,000 | -54.6% | 44,500 | -17.4% | 0.00% | 0.0% |
| Q3 2018 | $918,000 | +0.2% | 53,900 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $916,000 | +81.0% | 53,900 | +43.0% | 0.00% | 0.0% |
| Q1 2018 | $506,000 | +72.7% | 37,700 | +23.6% | 0.00% | – |
| Q4 2017 | $293,000 | -12.5% | 30,500 | 0.0% | 0.00% | – |
| Q3 2017 | $335,000 | +31.4% | 30,500 | +8.2% | 0.00% | – |
| Q2 2017 | $255,000 | -5.9% | 28,200 | +33.6% | 0.00% | – |
| Q1 2017 | $271,000 | -2.2% | 21,101 | -28.3% | 0.00% | – |
| Q4 2016 | $277,000 | -22.4% | 29,430 | -19.8% | 0.00% | -100.0% |
| Q3 2016 | $357,000 | +44.0% | 36,696 | -0.7% | 0.00% | – |
| Q2 2016 | $248,000 | -65.8% | 36,966 | -54.5% | 0.00% | -100.0% |
| Q1 2016 | $725,000 | -32.6% | 81,226 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $1,076,000 | +25.8% | 81,226 | 0.0% | 0.00% | +100.0% |
| Q3 2015 | $855,000 | -56.5% | 81,226 | +12.5% | 0.00% | -66.7% |
| Q2 2015 | $1,964,000 | – | 72,191 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |